The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Outcomes of patients with CLL discontinuing BTK inhibitors due to adverse effects
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses a single-center experience of the outcomes of patients with chronic lymphocytic leukemia (CLL) discontinuing BTK inhibitor (BTKi) treatment due to adverse effects. Dr Woyach notes that, as expected, patients who have been on the drug longer experience longer remission durations after discontinuation, and some patients can remain in remission for several years before treatment is needed or progression is noted. These findings confirm that stopping BTK inhibitors due to toxicity is feasible. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We know that with continuous BTK inhibitors, primarily with ibrutinib, but now much more data with the second-generation inhibitors, acalabrutinib and zanabrutinib, even though they are fairly well tolerated, many patients will discontinue therapy at some point, either because of a toxicity or just because of fatigue of taking a drug for so long when they are in remission...
We know that with continuous BTK inhibitors, primarily with ibrutinib, but now much more data with the second-generation inhibitors, acalabrutinib and zanabrutinib, even though they are fairly well tolerated, many patients will discontinue therapy at some point, either because of a toxicity or just because of fatigue of taking a drug for so long when they are in remission. In this study, we were interested in just using our own data from The Ohio State University to look at outcomes of patients who did discontinue ibrutinib or acalabrutinib due to toxicity. We found, as you might expect, that patients who had been on the drug longer experienced a longer remission duration when the drug was stopped. But we do see that there are many patients who can go over a year and sometimes with a median of two years before new treatment is needed or before progression is even noted. And I think that these data really give some more legitimacy to the practice of stopping a BTK inhibitor when somebody develops toxicity rather than immediately switching them to another therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AstraZeneca: Consultancy; Newave: Consultancy; Genentech, Inc.: Consultancy; Janssen: Research Funding; Loxo Lilly: Consultancy; BeiGene: Consultancy; AbbVie: Research Funding; Merck: Consultancy; Pharmacyclics: Consultancy, Research Funding; Schrodinger: Research Funding; Morphosys: Research Funding.
